Vasoactive Intestinal Peptide in COPD

• Status: Completed
• Trial end date: 2006-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study, a new immunomodulatory therapy of COPD with vasoactive intestinal peptide (VIP) was evaluated. Based on preliminary unpublished clinical and experimental results, the course of disease under VIP treatment and the molecular mechanisms involved were assessed.

34 patients with severe COPD were treated either with VIP inhalation in addition to conventional therapy or inhalation of placebo plus conventional therapy for a period of 3 months. The trial was conducted as a double blind, comparative study with two parallel groups.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University of Vienna
• Treatments: Vasoactive Intestinal Peptide

Criteria

Inclusion Criteria:

• Confirmed moderate to severe COPD with or without pulmonary hypertension

• Male and female patients.

• Aged 18 - 75 years.

• Written consent.

• Adequate contraception in female patients of childbearing age.

• Negative pregnancy test (four-weekly test repetition).

Exclusion Criteria:

• Lack of consent

• Pregnancy (four-weekly tests)

• Lactation

• Presumed non-cooperativeness

• Patients outside the stipulated age range

• Myocardial infarction within the last 12 months

• Stroke within the last 12 months

• Malignant diseases in anamnesis

• Legal incapacity

• Parallel participation in a clinical trial

• Parallel participation in a clinical trial within the last 4 weeks